Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Salmanton-García, J; Seidel, D; Koehler, P; Mellinghoff, SC; Herbrecht, R; Klimko, N; Ráčil, Z; Falces-Romero, I; Ingram, P; Benítez-Peñuela, MÁ; Rodríguez, JY; Desoubeaux, G; Barać, A; García-Vidal, C; Hoenigl, M; Mehta, SR; Cheng, MP; Klyasova, G; Heinz, WJ; Iqbal, N; Krause, R; Ostermann, H; Penack, O; Schalk, E; Sheppard, DC; Willinger, B; Wisplinghoff, H; Vehreschild, JJ; Cornely, OA; Vehreschild, MJGT; FungiScope® ECMM/ISHAM Working Group.
Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn).
J Antimicrob Chemother. 2019; 74(11):3315-3327
Doi: 10.1093/jac/dkz344
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Hönigl Martin
- Krause Robert
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- First-line antifungal treatment for invasive mucormycosis (IM) consists of liposomal amphotericin B. Salvage treatment options are limited and often based on posaconazole oral suspension. With the approval of posaconazole new formulations, patients could benefit from improved pharmacokinetics, safety and tolerability. Our aim was to assess the effectiveness of posaconazole new formulations for IM treatment. We performed a case-matched analysis with proven or probable IM patients from the FungiScope® Registry. First-line posaconazole new formulations (1st-POSnew) and first-line amphotericin B plus posaconazole new formulations (1st-AMB+POSnew) cases were matched with first-line amphotericin B-based (1st-AMB) treatment controls. Salvage posaconazole new formulations (SAL-POSnew) cases were matched with salvage posaconazole oral suspension (SAL-POSsusp) controls. Each case was matched with up to three controls (based on severity, haematological/oncological malignancy, surgery and/or renal dysfunction). Five patients receiving 1st-POSnew, 18 receiving 1st-AMB+POSnew and 22 receiving SAL-POSnew were identified. By day 42, a favourable response was reported for 80.0% (n = 4/5) of patients receiving 1st-POSnew, for 27.8% (n = 5/18) receiving 1st-AMB+POSnew and for 50.0% (n = 11/22) receiving SAL-POSnew. Day 42 all-cause mortality of patients receiving posaconazole new formulations was lower compared with controls [20.0% (n = 1/5) in 1st-POSnew versus 53.3% (n = 8/15) in 1st-AMB; 33.3% (n = 6/18) in 1st-AMB+POSnew versus 52.0% (n = 26/50) in 1st-AMB; and 0.0% (n = 0/22) in SAL-POSnew versus 4.4% (n = 2/45) in SAL-POSsusp]. Posaconazole new formulations were effective in terms of treatment response and associated mortality of IM. While posaconazole new formulations may be an alternative for treatment of IM, the limited sample size of our study calls for a cautious interpretation of these observations. © The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.
- Find related publications in this database (using NLM MeSH Indexing)
- Adolescent -
- Adult -
- Aged -
- Amphotericin B - therapeutic use
- Antifungal Agents - administration & dosage
- Antifungal Agents - chemistry
- Child -
- Child, Preschool -
- Drug Compounding -
- Female -
- Humans -
- Infant -
- Infant, Newborn -
- Invasive Fungal Infections - drug therapy
- Male -
- Matched-Pair Analysis -
- Middle Aged -
- Mucorales - drug effects
- Mucormycosis - blood
- Mucormycosis - drug therapy
- Prospective Studies -
- Registries -
- Triazoles - administration & dosage
- Triazoles - chemistry
- Young Adult -